Provectus Updates Shareholders in Its Annual CEO Letter Fort Mills Times In the nonclinical research studies conducted at the Moffitt Cancer Center by Dr. Shari Pilon-Thomas, PV-10 showed efficacy in murine models of breast and lung cancer as well as melanoma, providing several avenues for additional indications. Studies ... |
